177Lu-PSMA-617 delays disease progression at a significantly higher rate than standard of care in patients with oligometastatic hormone-sensitive prostate cancer.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/177lu-psma-617-delays-disease-progression-patients-2026a1000at7?src=rss
Author :
Publish date : 2026-04-13 12:00:00
Copyright for syndicated content belongs to the linked Source.